Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 14,331 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $3.53, for a total value of $50,588.43. Following the sale, the insider now owns 1,285,794 shares of the company’s stock, valued at approximately $4,538,852.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total value of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Stock Down 3.8 %

Shares of Genelux stock opened at $3.32 on Friday. Genelux Co. has a 52 week low of $3.07 and a 52 week high of $40.98. The company has a 50 day moving average price of $5.76 and a 200 day moving average price of $10.90.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). On average, equities analysts predict that Genelux Co. will post -0.81 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. HC Wainwright lowered their price target on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Benchmark restated a “speculative buy” rating and issued a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in Genelux by 1,660.1% during the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock worth $24,025,000 after buying an additional 925,258 shares during the last quarter. D.A. Davidson & CO. purchased a new position in shares of Genelux during the third quarter worth $237,000. Advisor Resource Council acquired a new position in Genelux during the fourth quarter valued at $233,000. Barclays PLC boosted its holdings in Genelux by 516.4% in the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after purchasing an additional 2,835 shares during the last quarter. Finally, Whittier Trust Co. acquired a new stake in Genelux during the 3rd quarter worth about $175,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.